OR WAIT null SECS
Novel molecular glues are transforming targeted protein degradation.
Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.
Predictive modeling facilitates the identification of coformers, cocrystal components, and complexing agents.
March 26, 2024
In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
March 25, 2024
Webinar Date/Time: Tue, Apr 16, 2024 11:00 AM EDT
Webinar Date/Time: Thu, Apr 25, 2024 11:00 AM EDT
March 21, 2024
Webinar Date/Time: Wed, May 8, 2024 11:00 AM EDT
March 16, 2024
Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection
March 15, 2024
The draft guidance document provides support to sponsors with drugs in clinical development that treat the states of sporadic Alzheimer’s disease.
March 14, 2024
In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.
Webinar Date/Time: Wed, Apr 24, 2024 11:00 AM EDT
March 08, 2024
EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.
March 07, 2024
Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.